Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) were down 2.6% during mid-day trading on Thursday . The company traded as low as $11.02 and last traded at $11.03, with a volume of 97,039 shares. The stock had previously closed at $11.33.

A number of analysts have recently issued reports on MNTA shares. Brean Capital restated a “buy” rating and set a $19.00 target price on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 4th. Goldman Sachs Group Inc. assumed coverage on shares of Momenta Pharmaceuticals in a research report on Monday, June 6th. They set a “neutral” rating and a $14.00 price target on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 4th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 27th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $18.00 price target (down from $21.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 4th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $18.40.

The company’s market cap is $766.24 million. The stock’s 50 day moving average is $11.10 and its 200 day moving average is $10.83.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by $0.03. The company had revenue of $19.90 million for the quarter, compared to the consensus estimate of $28.12 million. The business’s revenue was up 132.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.40) earnings per share. On average, equities research analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.33) earnings per share for the current fiscal year.

In related news, President Craig A. Wheeler sold 5,880 shares of the business’s stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $10.18, for a total value of $59,858.40. Following the transaction, the president now directly owns 349,521 shares of the company’s stock, valued at approximately $3,558,123.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP John E. Bishop sold 2,843 shares of the business’s stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $9.57, for a total transaction of $27,207.51. Following the completion of the transaction, the vice president now directly owns 160,880 shares in the company, valued at $1,539,621.60. The disclosure for this sale can be found here.

Several institutional investors recently modified their holdings of the company. Principal Financial Group Inc. increased its position in shares of Momenta Pharmaceuticals by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 423,158 shares of the biotechnology company’s stock worth $6,279,000 after buying an additional 18,504 shares during the period. Wells Fargo & Company MN increased its stake in Momenta Pharmaceuticals by 350.4% in the fourth quarter. Wells Fargo & Company MN now owns 110,300 shares of the biotechnology company’s stock valued at $1,637,000 after buying an additional 85,813 shares during the period. Morgan Stanley increased its stake in Momenta Pharmaceuticals by 123.0% in the fourth quarter. Morgan Stanley now owns 69,759 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 38,470 shares during the period. GSA Capital Partners LLP increased its stake in Momenta Pharmaceuticals by 298.9% in the fourth quarter. GSA Capital Partners LLP now owns 88,251 shares of the biotechnology company’s stock valued at $1,310,000 after buying an additional 66,130 shares during the period. Finally, New York State Common Retirement Fund increased its stake in Momenta Pharmaceuticals by 2.0% in the fourth quarter. New York State Common Retirement Fund now owns 150,991 shares of the biotechnology company’s stock valued at $2,241,000 after buying an additional 2,900 shares during the period.

Momenta Pharmaceuticals, Inc (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Company’s product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.